A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis

A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis

Objective: This study aimed to test a novel treatment combination (TC) (equivalent to sildenafil, mepivacaine, and glucose) with disease-modifying properties compared to Celestone® bifas® (CB) in a randomized triple-blinded phase III clinical study in horses with mild osteoarthritis (OA). Joint biom...

Full description

Bibliographic Details
Main Authors: E. Skiöldebrand, S. Adepu, C. Lützelschwab, S. Nyström, A. Lindahl, K. Abrahamsson-Aurell, E. Hansson
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Osteoarthritis and Cartilage Open
Subjects:
Osteoarthritis
DMOAD
Companion diagnostics
Biomarkers
Anaesthetic agents
Sildenafil
Online Access:http://www.sciencedirect.com/science/article/pii/S2665913123000481

Internet

http://www.sciencedirect.com/science/article/pii/S2665913123000481

Similar Items